Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b
- PMID: 15240198
- DOI: 10.1016/j.jns.2004.04.012
Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b
Abstract
To address the immune mechanism sustaining interferon beta (IFNbeta) efficacy in multiple sclerosis (MS), we longitudinally analyzed expressions of IFN-gamma, IL-4, IL-5 and IL-13 in CD4+ T cells and CD8+ T cells in 22 Japanese MS patients (16 patients with conventional MS and 6 with opticospinal MS) undergoing IFNbeta using flow cytometry. During the 48-week observation period, five opticospinal MS patients (83%) relapsed compared to only four conventional MS patients (25%); the frequency of relapsed patients was significantly higher in the former (p=0.046). The effects of IFNbeta on individual cytokines were time-dependent and altered cytokine productions were particularly evident in CD4+ rather than CD8+ T cells. A decreased intracellular IFN-gamma/IL-4 ratio in CD4+ T cells was thus evident soon after the initiation of therapy, and persisted for the entire 1 year follow-up period, regardless of whether or not the patient relapsed (p<0.01). IFNbeta treatment resulted in a rapid increase in the percentage of IFN-gamma- IL-4+ and IL-13+ CD4+ T cells 1 week after the initiation of therapy and high values were sustained for 6 months but declined to the baseline over 1 year. Later, the percentage of IFN-gamma+ IL-4- CD4+ T cells decreased significantly from weeks 24 through 48 of therapy (p<0.01). When comparisons with the pretreatment values were made for each subtype of MS, a significant reduction of IFN-gamma+ IL-4- CD4+ T cell percentages was shown in conventional MS (p<0.0001), but not in opticospinal MS. Moreover, when such a comparison was made by the presence or absence of relapse during therapy, a significant reduction of IFN-gamma+ IL-4- CD4+ T cell percentages was observed in MS patients without relapse (p<0.01). Thus, a reduction of IFN-gamma+ IL-4- CD4+ T cell percentages in the late phase of therapy is considered important for reducing relapse in conventional MS. When the expression patterns of IFN-gamma, IL-4, IL-5 and IL-13 in CD4+ T cells and CD8+ T cells were compared between patients with and without relapse during therapy, the only significant difference was an increase in the IL-13+ CD4+ T cell percentages in patients with relapse compared to those without (p<0.05). The results indicate that in CD4+ T cells IL-4 was preferentially up-regulated in the early course and IFN-gamma was down-regulated in the late phase of IFNbeta therapy. The net effect of IFNbeta on the immune balance was entirely toward type 2 immune deviation, possibly contributing to its beneficial effects on MS.
Similar articles
-
Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.J Neurol Sci. 2006 Jul 15;246(1-2):71-7. doi: 10.1016/j.jns.2006.02.008. Epub 2006 Mar 6. J Neurol Sci. 2006. PMID: 16581087
-
Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry.J Rheumatol. 2000 May;27(5):1128-35. J Rheumatol. 2000. PMID: 10813277
-
Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.J Neuroimmunol. 2005 Feb;159(1-2):155-64. doi: 10.1016/j.jneuroim.2004.09.016. Epub 2004 Dec 28. J Neuroimmunol. 2005. PMID: 15652415
-
Modulation of T-cell cytokine secretion by accessory cell-derived products.Eur Respir J Suppl. 1996 Aug;22:90s-94s. Eur Respir J Suppl. 1996. PMID: 8871051 Review.
-
Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis.Clin Neurol Neurosurg. 2010 Sep;112(7):641-5. doi: 10.1016/j.clineuro.2010.04.020. Epub 2010 Jun 1. Clin Neurol Neurosurg. 2010. PMID: 20570038 Review.
Cited by
-
Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients.Front Immunol. 2018 Jun 4;9:1240. doi: 10.3389/fimmu.2018.01240. eCollection 2018. Front Immunol. 2018. PMID: 29915590 Free PMC article.
-
Interferon beta-1a-induced morphea.JAAD Case Rep. 2014 Oct 5;1(1):15-7. doi: 10.1016/j.jdcr.2014.10.002. eCollection 2015 Jan. JAAD Case Rep. 2014. PMID: 27075128 Free PMC article. No abstract available.
-
Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.PLoS One. 2015 Apr 28;10(4):e0124923. doi: 10.1371/journal.pone.0124923. eCollection 2014. PLoS One. 2015. PMID: 25919001 Free PMC article.
-
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.BMC Neurol. 2012 Sep 18;12:95. doi: 10.1186/1471-2377-12-95. BMC Neurol. 2012. PMID: 22989378 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials